Results 11 to 20 of about 85,538 (123)

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial [PDF]

JAMA Oncology, 2019
In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown.To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib.
John B A G Haanen, Michael Jewett, Thomas Powles   +2 more
exaly   +10 more sources

Robot-assisted deferred cytoreductive nephrectomy in metastatic renal cell carcinoma following immune checkpoint inhibitors plus tyrosine-kinase inhibitor

Urology Video Journal
Objective: This video aims to demonstrate the safety and feasibility of performing deferred cytoreductive nephrectomy (dCN) using robotic assistance in patient treated with immunotherapy for metastatic renal cell carcinoma (mRCC).
Rocco Simone Flammia, Flavia Proietti, Veronica Palombi, Leslie Claire Licari, Eugenio Bologna, Aldo Brassetti, Giuseppe Simone, Costantino Leonardo   +7 more
doaj   +3 more sources

Expression of Tertiary Lymphoid Structure in Deferred Cytoreductive Nephrectomy of Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab [PDF]

IJU Case Reports, 2021
IntroductionTertiary lymphoid structure expression and immune checkpoint inhibitors have been attracting attention, and their relationship with renal cell carcinoma is controversial.Case presentationTwo patients with nivolumab plus ipilimumab treatment response for metastatic renal cell carcinoma underwent cytoreductive nephrectomy and regional lymph ...
Hiroaki Sato, Takayuki Arai, Shinichi Sakamoto   +2 more
exaly   +5 more sources

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma [PDF]

Urology Research and Practice, 2021
Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have
Charles Van Praet, Axel Bex, Gert De Meerleer, Maarten Albersen, Iulia Andras, Valérie Fonteyne, Sylvie Rottey, Nikhil Vasdev, Charlotte Slots, Karel Decaestecker   +9 more
doaj   +2 more sources

Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature

Current Oncology, 2021
The role and timing of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving immunotherapy-based regimens is unclear. However, the ability to achieve a complete response for metastatic renal cell carcinoma likely requires a
Scott J. Dawsey, Steven C. Campbell, Moshe C. Ornstein   +2 more
doaj   +2 more sources

457 focus (Online); Other title: Four fifty-seven focus; Other title: Ohio Deferred Compensation 457 focus; Other title: Ohio Deferred Compensation four fifty-seven focus; Other title: Title from "Program newsletters" screen: Participant Focus newsletter

, 2010
2010, 1st quarter-; At head of title: Ohio Deferred Compensation.; "A publication of the Ohio Deferred Compensation Board.

core   +22 more sources

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives [PDF]

Medicina, 2023
In the past decades, several treatments have been proposed for the management of metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) represents a controversial and open issue in the era of targeted therapy and novel ...
Luigi Napolitano, Celeste Manfredi, Luigi Cirillo, Giovanni Maria Fusco, Francesco Passaro, Marco Abate, Roberto La Rocca, Francesco Mastrangelo, Lorenzo Spirito, Savio Domenico Pandolfo, Felice Crocetto, Davide Arcaniolo, Biagio Barone   +12 more
doaj   +2 more sources

Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study. [PDF]

Int J Urol
Objectives: We aimed to evaluate overall survival (OS) and determine the optimal timing of cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitor (ICI)-based therapy.
Nukaya T, Takahara K, Toyoda S, Inoki L, Fukuokaya W, Mori K, Iwata T, Bekku K, Maenosono R, Tsujino T, Hirasawa Y, Yanagisawa T, Hashimoto T, Komura K, Araki M, Fujita K, Ohno Y, Shiroki R.   +17 more
europepmc   +3 more sources

Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma

Journal of Cancer Metastasis and Treatment, 2021
Cytoreductive nephrectomy has been a mainstay in treating patients with synchronous metastatic renal cell carcinoma (mRCC) for over two decades. It was supported in part by level 1 evidence that showed improved survival for patients undergoing radical ...
Brian W. Cross, Michael S. Cookson
openaire   +3 more sources

Cytoreductive nephrectomy in the current treatment algorithm [PDF]

Therapeutic Advances in Medical Oncology, 2019
The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted ...
Teele Kuusk, Bernadett Szabados, Wing Kin Liu, Thomas Powles, Axel Bex   +4 more
doaj   +3 more sources